X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (46672) 46672
Book Review (4920) 4920
Publication (1855) 1855
Newsletter (409) 409
Conference Proceeding (71) 71
Book Chapter (57) 57
Dissertation (36) 36
Magazine Article (16) 16
Newspaper Article (11) 11
Trade Publication Article (4) 4
Web Resource (4) 4
Book / eBook (3) 3
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (41518) 41518
humans (37338) 37338
female (25996) 25996
cisplatin - administration & dosage (24768) 24768
male (23037) 23037
cisplatin (21380) 21380
oncology (21360) 21360
middle aged (20915) 20915
antineoplastic combined chemotherapy protocols - therapeutic use (20663) 20663
aged (17914) 17914
adult (16613) 16613
chemotherapy (16216) 16216
cancer (12221) 12221
treatment outcome (8615) 8615
animals (7802) 7802
antineoplastic combined chemotherapy protocols - adverse effects (7291) 7291
combined modality therapy (7174) 7174
cisplatin - adverse effects (6411) 6411
lung neoplasms - drug therapy (6318) 6318
neoplasm staging (6171) 6171
fluorouracil - administration & dosage (5892) 5892
drug administration schedule (5367) 5367
survival rate (5001) 5001
antineoplastic agents - administration & dosage (4879) 4879
carcinoma (4777) 4777
antineoplastic combined chemotherapy protocols - administration & dosage (4543) 4543
prognosis (4498) 4498
pharmacology & pharmacy (4416) 4416
care and treatment (4281) 4281
doxorubicin - administration & dosage (4275) 4275
aged, 80 and over (4165) 4165
cisplatin - therapeutic use (4121) 4121
etoposide - administration & dosage (4114) 4114
carcinoma, non-small-cell lung - drug therapy (4039) 4039
radiotherapy (3938) 3938
mice (3934) 3934
survival analysis (3810) 3810
therapy (3784) 3784
retrospective studies (3745) 3745
disease-free survival (3742) 3742
ovarian neoplasms - drug therapy (3606) 3606
carcinoma, squamous cell - drug therapy (3557) 3557
paclitaxel (3486) 3486
paclitaxel - administration & dosage (3484) 3484
carboplatin (3439) 3439
carboplatin - administration & dosage (3434) 3434
surgery (3430) 3430
research (3399) 3399
antineoplastic agents - therapeutic use (3393) 3393
survival (3368) 3368
follow-up studies (3241) 3241
trial (3241) 3241
deoxycytidine - analogs & derivatives (3162) 3162
chemotherapy, adjuvant (3086) 3086
apoptosis (3073) 3073
lung neoplasms - pathology (3061) 3061
dose-response relationship, drug (3053) 3053
medicine & public health (2900) 2900
cisplatin - pharmacology (2892) 2892
abridged index medicus (2883) 2883
tumors (2819) 2819
deoxycytidine - administration & dosage (2810) 2810
adenocarcinoma - drug therapy (2777) 2777
cell line, tumor (2767) 2767
analysis (2759) 2759
antineoplastic agents - adverse effects (2745) 2745
cyclophosphamide - administration & dosage (2654) 2654
adolescent (2634) 2634
rats (2628) 2628
toxicity (2620) 2620
antineoplastic agents (2530) 2530
vinblastine - administration & dosage (2523) 2523
stomach neoplasms - drug therapy (2471) 2471
gemcitabine (2463) 2463
time factors (2436) 2436
prospective studies (2270) 2270
antimitotic agents (2265) 2265
health aspects (2258) 2258
combination (2249) 2249
bleomycin - administration & dosage (2201) 2201
antineoplastic agents - pharmacology (2159) 2159
doxorubicin (2142) 2142
hematology, oncology and palliative medicine (2121) 2121
drug therapy (2119) 2119
ovarian cancer (2116) 2116
5-fluorouracil (2086) 2086
remission induction (2068) 2068
carcinoma, non-small-cell lung - pathology (2039) 2039
phase-ii (2031) 2031
metastasis (2001) 2001
carcinoma, squamous cell - pathology (1936) 1936
methotrexate - administration & dosage (1927) 1927
etoposide (1925) 1925
docetaxel (1914) 1914
obstetrics & gynecology (1910) 1910
infusions, intravenous (1890) 1890
fluorouracil (1884) 1884
lung cancer (1875) 1875
cisplatin - toxicity (1858) 1858
apoptosis - drug effects (1810) 1810
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (41315) 41315
Japanese (3607) 3607
French (584) 584
Chinese (508) 508
German (446) 446
Russian (193) 193
Italian (134) 134
Spanish (129) 129
Polish (77) 77
Korean (39) 39
Hungarian (38) 38
Bulgarian (17) 17
Portuguese (16) 16
Dutch (14) 14
Czech (12) 12
Ukrainian (12) 12
Romanian (8) 8
Hebrew (7) 7
Persian (7) 7
Turkish (6) 6
Lithuanian (5) 5
Serbian (5) 5
Slovak (4) 4
Danish (2) 2
Finnish (2) 2
Swedish (2) 2
Bosnian (1) 1
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 534 - 544
The purpose of this national retrospective study was to evaluate the outcome in children with relapsed or primary refractory Hodgkin lymphoma [ HL ] after a... 
refractory disease | relapse | children | odgkin lymphoma | survival | Relapse | Children | Refractory disease | Survival | Hodgkin lymphoma | COMBINED-MODALITY THERAPY | PROGNOSTIC-FACTORS | RADIATION | CHEMOTHERAPY | TRIAL | FRENCH SOCIETY | DISEASE | SALVAGE THERAPY | RADIOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Procarbazine - administration & dosage | Prednisolone - adverse effects | Recurrence | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Humans | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Hodgkin Disease - surgery | Hodgkin Disease - mortality | Vincristine - administration & dosage | Child | Dacarbazine - administration & dosage | Dexamethasone - administration & dosage | Hematopoietic Stem Cell Transplantation | Etoposide - administration & dosage | Combined Modality Therapy | Bleomycin - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Ifosfamide - administration & dosage | Adolescent | Vincristine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Multicenter Studies as Topic | Hodgkin Disease - drug therapy | Retrospective Studies | Radiotherapy, Adjuvant | Doxorubicin - administration & dosage | Chlorambucil - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Ifosfamide - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Clinical Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Carmustine - administration & dosage | Patient outcomes | Diseases | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 3, pp. 239 - 246
Summary Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian... 
Hematology, Oncology and Palliative Medicine | IPASS | GEFITINIB | THERAPY | ONCOLOGY | SENSITIVITY | CARBOPLATIN/PACLITAXEL | TUMORS | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Exons | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Cisplatin - administration & dosage | Patient Selection | Time Factors | Female | Quinazolines - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Erlotinib | Lung cancer | Product development | Agriculture | Lung cancer, Non-small cell | Antineoplastic agents | Standards | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 01/2013, Volume 121, Issue 1, pp. 48 - 53
Treatment of mantle cell lymphoma (MCL) in younger patients remains a challenge. We report results of a phase 2 trial using cytarabine and rituximab as... 
WORKSHOP | EUROPEAN-MCL-NETWORK | IMMUNOCHEMOTHERAPY | THERAPY | RESCUE | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | HEMATOLOGY | Whole-Body Irradiation | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Mantle-Cell - surgery | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Kidney Diseases - chemically induced | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Kaplan-Meier Estimate | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Cytarabine - administration & dosage | Neoplasms, Second Primary - epidemiology | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Transplantation Conditioning | Peripheral Blood Stem Cell Transplantation | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 05/2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Index Medicus | Abridged Index Medicus | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 6/2013, Volume 21, Issue 6, pp. 1655 - 1663
Olanzapine has been shown to be a safe and effective agent for the prevention of chemotherapy-induced nausea and vomiting (CINV). Olanzapine may also be an... 
Breakthrough nausea and emesis | Pain Medicine | Chemotherapy | Nursing | Rehabilitation Medicine | Olanzapine | Medicine & Public Health | Oncology | Metoclopramide | Nursing Management/Nursing Research | DEXAMETHASONE | PREVENTION | APREPITANT | ANTIEMETIC ACTIVITY | CANCER-PATIENTS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | DOUBLE-BLIND | REHABILITATION | PALONOSETRON | QUALITY-OF-LIFE | DELAYED NAUSEA | CISPLATIN-INDUCED EMESIS | Cyclophosphamide - administration & dosage | Isoquinolines - adverse effects | Nausea - chemically induced | Humans | Middle Aged | Antiemetics - administration & dosage | Dexamethasone - adverse effects | Male | Antineoplastic Agents - administration & dosage | Cyclophosphamide - adverse effects | Quinuclidines - administration & dosage | Cisplatin - administration & dosage | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Antiemetics - adverse effects | Female | Nausea - drug therapy | Vomiting - prevention & control | Quinuclidines - adverse effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Double-Blind Method | Morpholines - administration & dosage | Metoclopramide - administration & dosage | Vomiting - drug therapy | Neoplasms - drug therapy | Nausea - prevention & control | Vomiting - chemically induced | Metoclopramide - adverse effects | Cisplatin - adverse effects | Benzodiazepines - administration & dosage | Aged | Benzodiazepines - adverse effects | Isoquinolines - administration & dosage | Doxorubicin - adverse effects | Care and treatment | Cyclophosphamide | Anthracyclines | Dexamethasone | Nausea | Cancer | Side effects | Drug therapy | Vomiting | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10031, pp. 1909 - 1920
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2010, Volume 151, Issue 2, pp. 159 - 166
Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell... 
cyclophosphamide | clinical trials | vincristine | doxorubicin | prednisone (CHOP) | T-cell lymphoma | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | IFOSFAMIDE | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | THERAPY | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Cisplatin - administration & dosage | Young Adult | Vinblastine - adverse effects | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Ifosfamide - adverse effects | Etoposide - administration & dosage | Treatment Outcome | Bleomycin - administration & dosage | Bleomycin - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Adolescent | Survival Analysis | Cisplatin - adverse effects | Vincristine - adverse effects | Aged | Neoplasm Staging | Doxorubicin - adverse effects | Anthracyclines | Cyclophosphamide | Corticosteroids | Etoposide | Clinical trials | Product development | Prednisone | Non-Hodgkin's lymphomas | T cells | double prime B-cell lymphoma | Cell survival | Vinblastine | Ifosfamide | Toxicity | Doxorubicin | Survival | Vincristine | Cisplatin | Dacarbazine | Bleomycin | Remission | double prime T-cell lymphoma | Anaplastic large-cell lymphoma | expressed sequence tags | Index Medicus
Journal Article